Integra LifeSciences IART Instruments — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's instruments — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's instruments — total revenues?
- Integra LifeSciences (IART) reported instruments — total revenues of $47.23M in Q1 2026.
- How has Integra LifeSciences's instruments — total revenues changed year-over-year?
- Integra LifeSciences's instruments — total revenues decreased by 7.3% year-over-year, from $50.95M to $47.23M.
- What is the long-term trend for Integra LifeSciences's instruments — total revenues?
- Over 4 years (2021 to 2025), Integra LifeSciences's instruments — total revenues has grown at a -1.8% compound annual growth rate (CAGR), from $222.27M to $206.47M.
- What does instruments — total revenues mean?
- This metric represents the total net revenue generated from the sale of surgical instruments and related medical equipment within the company's dedicated instruments segment. It reflects the market demand for the firm's specialized hardware offerings used in surgical procedures and provides insight into the segment's contribution to overall top-line performance. Tracking this figure helps investors assess the stability and growth trajectory of the company's core surgical product portfolio.